Literature DB >> 6773243

In vitro and in vivo characterization of factor VIII preparations.

J P Allain, F Verroust, J P Soulier.   

Abstract

An in vitro and in vivo comparison of nine commercial and noncommercial factor VIII preparations was made. These consisted of one lyophilized cryoprecipitate, four intermediate (IPC) and four high purity concentrates (HPC). Protein, fibrinogen, factor VIII complex, IgG, IgM and anti-A and B alloagglutinins levels were measured. These three qualities of product were defined by two ratios: units of F VIII:C per mg of protein and per mg of fibrinogen. They were, respectively, less than 0.05 and less than 1 in cryoprecipitate, 0.5--1 and 1--3 in IPC, and greater than 1 and greater than 3 in HPC. The F VIII:C/F VIII:AG ration ranged from 0.3 to 0.6 and the F VIII:C/F VIII:VWF ratio was always lower than 1. Varying titers of alloagglutinins were found, unrelated to either IgG or IgM levels. Seven of these preparations were injected into several classical hemophilia A patients for treatment of minor hemorrhages. The peak of F VIII:C activity was always found 1 h postinjection. The F VIII:C recovery ranged from 80 to 140% and the half-life from 8 to 15 h. No significant difference was found among these products and the clinical efficacy was similar.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6773243     DOI: 10.1111/j.1423-0410.1980.tb02333.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  9 in total

1.  Quality control programme for the preparation of small-pool lyophilized heat-treated cryoprecipitates.

Authors:  D P Allersma; F Swüste; E Briët; J A Van der Does
Journal:  Pharm Weekbl Sci       Date:  1991-02-22

2.  Freeze dried cryoprecipitate: a clinical evaluation.

Authors:  H Hambley; J F Davidson; I D Walker; M Small; C R Prentice
Journal:  J Clin Pathol       Date:  1983-05       Impact factor: 3.411

3.  In vitro survival studies of a Factor VIII concentrate (Kryobulin).

Authors:  R Dal Bo Zanon; R Gazzetta; F Fabris; G Ruffato; A Girolami
Journal:  Blut       Date:  1982-10

Review 4.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Fibronectin in blood products--an in vitro and in vivo study.

Authors:  J T Reilly; B A McVerry; M J Mackie
Journal:  J Clin Pathol       Date:  1983-12       Impact factor: 3.411

6.  Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies.

Authors:  I M Nilsson; E Berntorp; O Zettervall
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

7.  In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients. The influence of reagents and standards.

Authors:  M Köhler; E Seifried; P Hellstern; G Pindur; C Miyashita; S Mörsdorf; F Fasco; E Wenzel
Journal:  Blut       Date:  1988-12

8.  Double cryoprecipitated factor VIII concentrate from heparinised plasma and its heat treatment.

Authors:  C T Smit Sibinga; P J Schulting; J Notebomer; P C Das; J Marrink; J vd Meer
Journal:  Blut       Date:  1988-03

Review 9.  The History of Clotting Factor Concentrates Pharmacokinetics.

Authors:  Massimo Morfini
Journal:  J Clin Med       Date:  2017-03-20       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.